Developer docs
API playgroundTry for free, no card

Search company profiles

Dr Ashleys

Full company profile

uuid000xofp

Namestring
Dr Ashleys
Legal namestring
Zoar Limited
Websiteurl
drashleys.com
Company typeenum
Private
Founded yearint
2012
Descriptiontext

Dr Ashleys (operating as Zoar Limited) is a Cayman Islands-incorporated pharmaceutical company founded in 2012 that manufactures specialized active pharmaceutical ingredients (APIs), orphan drugs for rare diseases, and anti-cancer medications. The company employs 101-250 people and produces over 300 million annual medical doses delivered to disease epicenters worldwide. Its proprietary low-cost manufacturing technology enables it to produce the industry's lowest-cost malaria drug and to rank as the world's third-largest contract manufacturer of quinine salts and the market leader in antimalarial APIs. The company holds 60 issued patents and 60+ pending patents, a portfolio expanded through its announced reverse merger with Impact BioMedical Inc. targeted for NYSE American listing by July 2026.

The company serves government health ministries and healthcare providers in Africa (addressing 94% of global malaria cases) and Southeast Asia, where its anti-cancer drugs are approved in Malaysia with pending distribution throughout the region. Its business model operates across three revenue streams: API manufacturing and direct sales, orphan drug manufacturing for rare diseases, and contract development and manufacturing organization (CDMO) services for pharmaceutical companies globally. The CDMO segment provides third-party manufacturing services helping pharmaceutical companies bring new drugs to market. Distribution occurs through B2B contracts with government health systems and direct sales to enterprise healthcare buyers rather than retail channels.

The company is led by CEO/CFO Daphne Huang (former CFO at Taro Pharmaceuticals, Human well Healthcare USA, and Gorilla Technology Group), COO Markland Anthony (30+ years in Southeast Asia markets, previously VP Operations at Fung Shing Chemicals Limited), and founder/visionary leader Dr. Kanans Visvanants FRSC, a second-generation pharmaceutical and chemical engineer. The company has minimal disclosed revenue, with its only public revenue figure being $32,000 from the newly acquired Celios air purification product line for fiscal year 2025.

Short descriptiontext

Dr Ashleys (Zoar Limited) is a pharmaceutical manufacturer specializing in low-cost APIs, orphan drugs for rare diseases, and anti-cancer medications, serving government health ministries and healthcare providers across Africa and Southeast Asia with over 300 million annual doses.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersGrand Cayman, Cayman Islands
HQ citystring
Grand Cayman
HQ countrystring
Cayman Islands
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pharmaceutical manufacturing, active pharmaceutical ingredients, orphan drugs, anti-malarial drugs, contract drug manufacturing
Industry5 codes
PRIMARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAA
Small-Molecule API & Intermediates CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAB
Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAIABAI
Contract Development & Manufacturing for Generics (CDMO/CMO)
SECONDARYHLAIAAAC
Oncology & Hematology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code3 codes
  • Pharmaceutical and Medicine Manufacturing32541
  • Pharmaceutical Preparation Manufacturing325412
  • Drugs and Druggists' Sundries Merchant Wholesalers42421
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Medicinal Chemicals & Botanical Products2833
Product category
Pharmaceutical Manufacturing
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Active Pharmaceutical Ingredients (API)
TypeHardware Sales
Description

Manufacturing and sale of active pharmaceutical ingredients for various therapeutic areas including oncology, hormonal therapies, antibiotics, cardiovascular, and neurological disorders

zoarlimited.com
2Orphan Drugs
TypeHardware Sales
Description

Specialized manufacturing of orphan drugs for rare diseases, addressing the underserved and limited production market

zoarlimited.com
3CDMO Services
TypeProfessional Services
Description

Contract Development and Manufacturing Organization services helping pharmaceutical companies bring new drugs to market efficiently

zoarlimited.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Operations, Supply Chain, Personnel, Technology or R&D, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Dr Ashleys (operating as Zoar Limited) develops and manufactures specialized and complex active pharmaceutical ingredients (APIs), orphan drugs for rare diseases, patented anti-malarial drugs, and low-cost anti-cancer drugs using proprietary manufacturing technology. The company also operates a Contract Development and Manufacturing Organization (CDMO) that helps pharmaceutical companies bring new drugs to market, delivering over 300 million annual medical doses to disease epicenters globally.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 263 million annual malaria cases addressed through low-cost drugs
+3 more records
Product overview1 text field

Dr Ashleys (operating as Zoar Limited) is a global pharmaceutical manufacturer and Contract Development and Manufacturing Organization (CDMO) offering a portfolio of specialized products including Active Pharmaceutical Ingredients (API), Orphan Drugs, and manufactured treatments. The company's product portfolio includes malaria drugs (industry's lowest cost), anti-cancer drugs (approved in Malaysia), and the recently acquired Celios air purification product line. Operations span across critical health areas including cancer, gastrointestinal disorders, acute respiratory infections, COVID-19, dengue fever, tuberculosis, and other infectious diseases, providing over 300 million annual medical doses to the world's disease epicenters.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
1Sentinel Brokers Company
Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-03-31
Description

Sentinel Brokers Company received FINRA approval to serve as an underwriter for corporate securities offerings, supporting the merged entity's public market activities.

sec.gov
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-06-23
Description

Dr. Ashleys Limited, a Hong Kong-based pharmaceutical company, announced a strategic merger agreement with Impact BioMedical Inc., a Texas-based biopharmaceutical developer. The merger aims to create a new publicly traded entity on NYSE American, leveraging Impact BioMedical's patent portfolio and expanding global reach and development capabilities. The merger is targeted for completion by July 1, 2026 and is structured as a reverse merger transaction.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Indian generic pharma manufacturer with strong presence in Africa, SE Asia, and other emerging markets. Comparable to Dr Ashleys in affordable generic drugs and emerging-market distribution.

TypeDirect peer
Description

Small-molecule API and finished dosage CDMO. Directly comparable to Dr Ashleys' small-molecule API and drug-product CDMO offering.

TypeDirect peer
Description

Indian API and generic manufacturer with a leading global position in antimalarial APIs. One of the closest direct peers to Dr Ashleys in the low-cost antimalarial API segment.

TypeDirect peer
Description

Large Indian generic and API manufacturer with a global footprint and significant antimalarial API share. Directly comparable to Dr Ashleys on low-cost API manufacturing and emerging-market drug distribution.

TypeBroad incumbent
Description

World's largest generic drug manufacturer with broad API and finished-dose capabilities. A broad incumbent peer in the generic and API space where Dr Ashleys competes on cost.

TypeDirect peer
Description

Indian specialty generic and API manufacturer with oncology focus. Closely comparable to Dr Ashleys in low-cost oncology and specialty generics.

TypeBroad incumbent
Description

Global generic and specialty pharma with significant antimalarial (including quinine) franchise and broad emerging-market distribution. A broad incumbent comparable to Dr Ashleys in antimalarials and global generics.

TypeDirect peer
Description

Major Indian generic pharmaceutical manufacturer with a strong antimalarial and respiratory franchise, particularly in Africa. Highly comparable to Dr Ashleys in low-cost generic API manufacturing and emerging-market distribution.

TypeBroad incumbent
Description

Global CDMO serving pharma and biotech customers across dosage forms. A broad incumbent CDMO peer reflecting Dr Ashleys' CDMO service line.

TypeDirect peer
Description

Indian generic and specialty pharma with significant API capabilities. Comparable to Dr Ashleys across generic APIs and emerging-market distribution.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Dr Ashleys

Pharmaceutical Manufacturingdrashleys.com

Dr Ashleys (Zoar Limited) is a pharmaceutical manufacturer specializing in low-cost APIs, orphan drugs for rare diseases, and anti-cancer medications, serving government health ministries and healthcare providers across Africa and Southeast Asia with over 300 million annual doses.

What Dr Ashleys does

Dr Ashleys (operating as Zoar Limited) is a Cayman Islands-incorporated pharmaceutical company founded in 2012 that manufactures specialized active pharmaceutical ingredients (APIs), orphan drugs for rare diseases, and anti-cancer medications. The company employs 101-250 people and produces over 300 million annual medical doses delivered to disease epicenters worldwide. Its proprietary low-cost manufacturing technology enables it to produce the industry's lowest-cost malaria drug and to rank as the world's third-largest contract manufacturer of quinine salts and the market leader in antimalarial APIs. The company holds 60 issued patents and 60+ pending patents, a portfolio expanded through its announced reverse merger with Impact BioMedical Inc. targeted for NYSE American listing by July 2026.

The company serves government health ministries and healthcare providers in Africa (addressing 94% of global malaria cases) and Southeast Asia, where its anti-cancer drugs are approved in Malaysia with pending distribution throughout the region. Its business model operates across three revenue streams: API manufacturing and direct sales, orphan drug manufacturing for rare diseases, and contract development and manufacturing organization (CDMO) services for pharmaceutical companies globally. The CDMO segment provides third-party manufacturing services helping pharmaceutical companies bring new drugs to market. Distribution occurs through B2B contracts with government health systems and direct sales to enterprise healthcare buyers rather than retail channels.

The company is led by CEO/CFO Daphne Huang (former CFO at Taro Pharmaceuticals, Human well Healthcare USA, and Gorilla Technology Group), COO Markland Anthony (30+ years in Southeast Asia markets, previously VP Operations at Fung Shing Chemicals Limited), and founder/visionary leader Dr. Kanans Visvanants FRSC, a second-generation pharmaceutical and chemical engineer. The company has minimal disclosed revenue, with its only public revenue figure being $32,000 from the newly acquired Celios air purification product line for fiscal year 2025.

Dr Ashleys firmographics

Firmographics
Name
Dr Ashleys
Legal name
Zoar Limited
Website
https://drashleys.com
Company type
Private
Founded year
2012
Operating status
Operating
Headcount range
11–50 employees
Short description
Dr Ashleys (Zoar Limited) is a pharmaceutical manufacturer specializing in low-cost APIs, orphan drugs for rare diseases, and anti-cancer medications, serving government health ministries and healthcare providers across Africa and Southeast Asia with over 300 million annual doses.
Ownership category
akta.pro rank

Dr Ashleys industry classification

Industry
Product category
Pharmaceutical Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing (32541), Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (42421)
SIC
Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)
akta.pro industry
PRIMARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAA
Small-Molecule API & Intermediates CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAB
Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAIABAI
Contract Development & Manufacturing for Generics (CDMO/CMO)
SECONDARYHLAIAAAC
Oncology & Hematology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Pharmaceutical manufacturing
  • Active pharmaceutical ingredients
  • Orphan drugs
  • Anti-malarial drugs
  • Contract drug manufacturing

Where Dr Ashleys is headquartered

Location

Headquarters

HQ city
Grand Cayman
HQ country
Cayman Islands

Offices1 record

Markets served

Dr Ashleys business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Operations, Supply Chain, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

  1. Active Pharmaceutical Ingredients (API): Manufacturing and sale of active pharmaceutical ingredients for various therapeutic areas including oncology, hormonal therapies, antibiotics, cardiovascular, and neurological disorders
  2. Orphan Drugs: Specialized manufacturing of orphan drugs for rare diseases, addressing the underserved and limited production market
  3. CDMO Services: Contract Development and Manufacturing Organization services helping pharmaceutical companies bring new drugs to market efficiently

Go-to-market motion1 record

Distribution channels4 records

Marketing channels3 records

Dr Ashleys product offering

Product offering

Core offering

Dr Ashleys (operating as Zoar Limited) develops and manufactures specialized and complex active pharmaceutical ingredients (APIs), orphan drugs for rare diseases, patented anti-malarial drugs, and low-cost anti-cancer drugs using proprietary manufacturing technology. The company also operates a Contract Development and Manufacturing Organization (CDMO) that helps pharmaceutical companies bring new drugs to market, delivering over 300 million annual medical doses to disease epicenters globally.

Product overview

Dr Ashleys (operating as Zoar Limited) is a global pharmaceutical manufacturer and Contract Development and Manufacturing Organization (CDMO) offering a portfolio of specialized products including Active Pharmaceutical Ingredients (API), Orphan Drugs, and manufactured treatments. The company's product portfolio includes malaria drugs (industry's lowest cost), anti-cancer drugs (approved in Malaysia), and the recently acquired Celios air purification product line. Operations span across critical health areas including cancer, gastrointestinal disorders, acute respiratory infections, COVID-19, dengue fever, tuberculosis, and other infectious diseases, providing over 300 million annual medical doses to the world's disease epicenters.

Differentiator

Problem solved

Functional benefit

Quantifiable outcome

  • 263 million annual malaria cases addressed through low-cost drugs
  • +3 more outcomes

Companies that use Dr Ashleys

Customer profile

Named customers2 records

Segments4 records

Ideal customer profiles4 records

Dr Ashleys technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Dr Ashleys partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered minor and core.

  • Sentinel Brokers CompanyminorChannel Partner/ Reseller/ Distributor · 31 March 2026Sentinel Brokers Company received FINRA approval to serve as an underwriter for corporate securities offerings, supporting the merged entity's public market activities.
  • Impact BioMedical Inc.coreStrategic or Co-development Partner · 23 June 2025Dr. Ashleys Limited, a Hong Kong-based pharmaceutical company, announced a strategic merger agreement with Impact BioMedical Inc., a Texas-based biopharmaceutical developer. The merger aims to create a new publicly traded entity on NYSE American, leveraging Impact BioMedical's patent portfolio and expanding global reach and development capabilities. The merger is targeted for completion by July 1, 2026 and is structured as a reverse merger transaction.

Scale indicators6 records

Recent moves8 records

Expansion highlights5 records

Dr Ashleys competitors and assessment

Company assessment

Direct peers

  • Strides Pharma: Indian generic pharma manufacturer with strong presence in Africa, SE Asia, and other emerging markets. Comparable to Dr Ashleys in affordable generic drugs and emerging-market distribution.
  • Cambrex: Small-molecule API and finished dosage CDMO. Directly comparable to Dr Ashleys' small-molecule API and drug-product CDMO offering.
  • Ipca Laboratories: Indian API and generic manufacturer with a leading global position in antimalarial APIs. One of the closest direct peers to Dr Ashleys in the low-cost antimalarial API segment.
  • Aurobindo Pharma: Large Indian generic and API manufacturer with a global footprint and significant antimalarial API share. Directly comparable to Dr Ashleys on low-cost API manufacturing and emerging-market drug distribution.
  • Natco Pharma: Indian specialty generic and API manufacturer with oncology focus. Closely comparable to Dr Ashleys in low-cost oncology and specialty generics.
  • Cipla: Major Indian generic pharmaceutical manufacturer with a strong antimalarial and respiratory franchise, particularly in Africa. Highly comparable to Dr Ashleys in low-cost generic API manufacturing and emerging-market distribution.
  • Lupin Pharmaceuticals: Indian generic and specialty pharma with significant API capabilities. Comparable to Dr Ashleys across generic APIs and emerging-market distribution.

Broad incumbents

  • Teva Pharmaceutical Industries: World's largest generic drug manufacturer with broad API and finished-dose capabilities. A broad incumbent peer in the generic and API space where Dr Ashleys competes on cost.
  • Mylan / Viatris: Global generic and specialty pharma with significant antimalarial (including quinine) franchise and broad emerging-market distribution. A broad incumbent comparable to Dr Ashleys in antimalarials and global generics.
  • Catalent: Global CDMO serving pharma and biotech customers across dosage forms. A broad incumbent CDMO peer reflecting Dr Ashleys' CDMO service line.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

Dr Ashleys social profiles

Digital presence

Dr Ashleys financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Dr Ashleys leadership team

Management profile

Number of profiles

Profiles3 records

Dr Ashleys funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Dr Ashleys M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Dr Ashleys

What does Dr Ashleys do?

Dr Ashleys (operating as Zoar Limited) develops and manufactures specialized and complex active pharmaceutical ingredients (APIs), orphan drugs for rare diseases, patented anti-malarial drugs, and low-cost anti-cancer drugs using proprietary manufacturing technology. The company also operates a Contract Development and Manufacturing Organization (CDMO) that helps pharmaceutical companies bring new drugs to market, delivering over 300 million annual medical doses to disease epicenters globally.

Is Dr Ashleys a public or private company?

Dr Ashleys is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Dr Ashleys founded?

Dr Ashleys was founded in 2012. It employs 11 to 50 people.

Where is Dr Ashleys based?

Dr Ashleys is headquartered in Grand Cayman, Cayman Islands.

How does Dr Ashleys make money?

Three revenue lines are on record. Active Pharmaceutical Ingredients (API) is the primary driver. The others are orphan Drugs and CDMO Services.

Who are Dr Ashleys's main competitors?

Direct peers on record are Strides Pharma, Cambrex, Ipca Laboratories, Aurobindo Pharma, Natco Pharma, Cipla and Lupin Pharmaceuticals. Broad incumbents are Teva Pharmaceutical Industries, Mylan / Viatris and Catalent.

Does Dr Ashleys have an API?

No public API is recorded for Dr Ashleys.

What industry is Dr Ashleys in?

Dr Ashleys's product category is Pharmaceutical Manufacturing. Its primary akta.pro industry code is HLAGABAG, Drug Substance–Drug Product Integrated CDMO, with a secondary code of HLAGABAA, Small-Molecule API & Intermediates CDMO. Its NAICS code is 32541 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals